Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTC Tumbles On Ataluren Failure In Cystic Fibrosis

Executive Summary

With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.

You may also be interested in...



Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

PTC Gambles On Success With Emflaza; Says Price Revision Is Needed

Looking to become a therapeutic area leader in DMD, PTC pays $140m up front for Marathon's controversial Emflaza, but the biotech's stock price plummeted, indicating that investors don't share PTC's optimism.

Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel